Gaucher Disease Market Segmentation By Product Type (Enzyme Replacement Therapy or ERT and Substrate Replacement Therapy or SRT); By Infusion Mode (Intravenous and Oral); By Clinical Type (Type I, Type II and Type III) and By End User (Hospitals, Domestic and Others) - Global Industry Demand Analysis and Opportunity Assessment 2018-2026
Buy Now Report ID: 2420 | Published Date: Feb 09, 2023Global Gaucher Disease Market
1. INTRODUCTION
1.1. MARKET DEFINITION
1.2. PURPOSE OF THE REPORT
1.3. CURRENCY
1.4. LIMITATIONS
1.5. STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1. RESEARCH SCOPE
2.2. MARKET SEGMENTATION
2.3. RESEARCH APPROACH
2.3.1 TOP-DOWN APPROACH
2.3.2 BOTTOM-UP APPROACH
2.4. PRIMARY RESEARCH
2.5. SECONDARY RESEARCH
2.6. ASSUMPTIONS
3. GLOBAL GAUCHER DISEASE MARKET – EXECUTIVE SUMMARY
3.1. SUMMARY
4. GLOBAL GAUCHER DISEASE MARKET OVERVIEW
4.1. MARKET DYNAMICS
4.1.1 DRIVING FORCES
4.1.1.1 Growing incidence of Gaucher disease
4.1.1.2 Increasing governmental support and growing demand for enzyme
replacement therapy for the treatment of rare diseases
4.1.2 RESTRAINING FACTOR
4.1.2.1 High cost of product and therapies
4.1.3 OPPORTUNITY MATRIX
4.1.3.1 Expansion of product portfolio especially in towards Pharmaceutical Products
5. INDUSTRY INSIGHTS
5.1. PORTER'S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIER
5.1.2 BARGAINING POWER OF BUYER
5.1.3 THREAT OF SUBSTITUTE
5.1.4 THREAT OF NEW ENTRANT
5.1.5 DEGREE OF COMPETITION
5.2. VALUE CHAIN ANALYSIS
6. GLOBAL GAUCHER DISEASE MARKET, BY PRODUCT
6.1. OVERVIEW
7. GLOBAL GAUCHER DISEASE MARKET, BY INFUSION MODES
7.1. OVERVIEW
8. GLOBAL GAUCHER DISEASE MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
9. GLOBAL GAUCHER DISEASE MARKET, BY CLINICAL TYPE
9.1. OVERVIEW
10. NORTH AMERICA GAUCHER DISEASE MARKET
10.1. OVERVIEW
10.1.1.1 North America Market Analysis, By Product Type
10.1.1.2 North America Market Analysis, By Intake Mode
10.1.1.3 North America Market Analysis, By Clinical Types
10.1.1.4 North America Market Analysis, By End-Users
10.2. U.S.
10.2.1.1 U.S. Market Analysis, By Product Type
10.2.1.2 U.S. Market Analysis, By Intake Mode
10.2.1.3 U.S. Market Analysis, By Clinical Types
10.2.1.4 U.S. Market Analysis, By End-Users
10.3. CANADA
10.3.1.1 Canada Market Analysis, By Product Type
10.3.1.2 Canada Market Analysis, By Intake Mode
10.3.1.3 Canada Market Analysis, By Clinical Types
10.3.1.4 Canada Market Analysis, By End-Users
11. LATIN AMERICA GAUCHER DISEASE MARKET
11.1. OVERVIEW
11.1.1.1 Latin America Market Analysis, By Product Type
11.1.1.2 Latin America Market Analysis, By Intake Mode
11.1.1.3 Latin America Market Analysis, By Clinical Types
11.1.1.4 Latin America Market Analysis, By End-Users
11.2. BRAZIL
11.2.1.1 Brazil Market Analysis, By Product Type
11.2.1.2 Brazil Market Analysis, By Intake Mode
11.2.1.3 Brazil Market Analysis, By Clinical Types
11.2.1.4 Brazil Market Analysis, By End-Users
11.3. MEXICO
11.3.1.1 Mexico Market Analysis, By Product Type
11.3.1.2 Mexico Market Analysis, By Intake Mode
11.3.1.3 Mexico Market Analysis, By Clinical Types
11.3.1.4 Mexico Market Analysis, By End-Users
11.4. ARGENTINA
11.4.1.1 Argentina Market Analysis, By Product Type
11.4.1.2 Argentina Market Analysis, By Intake Mode
11.4.1.3 Argentina Market Analysis, By Clinical Types
11.4.1.4 Argentina Market Analysis, By End-Users
12. EUROPE GAUCHER DISEASE MARKET
12.1. OVERVIEW
12.1.1.1 Europe Market Analysis, By Product Type
12.1.1.2 Europe Market Analysis, By Intake Mode
12.1.1.3 Europe Market Analysis, By Clinical Types
12.1.1.4 Europe Market Analysis, By End-Users
12.2. GERMANY
12.2.1.1 Germany Market Analysis, By Product Type
12.2.1.2 Germany Market Analysis, By Intake Mode
12.2.1.3 Germany Market Analysis, By Clinical Types
12.2.1.4 Germany Market Analysis, By End-Users 77
12.3. UNITED KINGDOM
12.3.1.1 United Kingdom Market Analysis, By Product Type
12.3.1.2 United Kingdom Market Analysis, By Intake Mode
12.3.1.3 United Kingdom Market Analysis, By Clinical Types
12.3.1.4 United Kingdom Market Analysis, By End-Users
12.4. FRANCE
12.4.1.1 France Market Analysis, By Product Type
12.4.1.2 France Market Analysis, By Intake Mode
12.4.1.3 France Market Analysis, By Clinical Types
12.4.1.4 France Market Analysis, By End-Users
12.5. ITALY
12.5.1.1 Italy Market Analysis, By Product Type
12.5.1.2 Italy Market Analysis, By Intake Mode
12.5.1.3 Italy Market Analysis, By Clinical Types
12.5.1.4 Italy Market Analysis, By End-Users
12.6. SPAIN
12.6.1.1 Spain Market Analysis, By Product Type
12.6.1.2 Spain Market Analysis, By Intake Mode
12.6.1.3 Spain Market Analysis, By Clinical Types
12.6.1.4 Spain Market Analysis, By End-Users
12.7. TURKEY
12.7.1.1 Turkey Market Analysis, By Product Type
12.7.1.2 Turkey Market Analysis, By Intake Mode
12.7.1.3 Turkey Market Analysis, By Clinical Types
12.7.1.4 Turkey Market Analysis, By End-Users
12.8. RUSSIA
12.8.1.1 Russia Market Analysis, By Product Type
12.8.1.2 Russia Market Analysis, By Intake Mode
12.8.1.3 Russia Market Analysis, By Clinical Types
12.8.1.4 Russia Market Analysis, By End-Users
13. ASIA PACIFIC GAUCHER DISEASE MARKET
13.1. OVERVIEW
13.1.1.1 Asia Pacific Market Analysis, By Product Type
13.1.1.2 Asia Pacific Market Analysis, By Intake Mode
13.1.1.3 Asia Pacific Market Analysis, By Clinical Types
13.1.1.4 Asia Pacific Market Analysis, By End-Users
13.2. CHINA
13.2.1.1 China Market Analysis, By Product Type
13.2.1.2 China Market Analysis, By Intake Mode
13.2.1.3 China Market Analysis, By Clinical Types
13.2.1.4 China Market Analysis, By End-Users
13.3. INDIA
13.3.1.1 India Market Analysis, By Product Type
13.3.1.2 India Market Analysis, By Intake Mode
13.3.1.3 India Market Analysis, By Clinical Types
13.3.1.4 India Market Analysis, By End-Users
13.4. JAPAN
13.4.1.1 Japan Market Analysis, By Product Type
13.4.1.2 Japan Market Analysis, By Intake Mode
13.4.1.3 Japan Market Analysis, By Clinical Types
13.4.1.4 Japan Market Analysis, By End-Users
13.5. SOUTH KOREA
13.5.1.1 South Korea Market Analysis, By Product Type
13.5.1.2 South Korea Market Analysis, By Intake Mode
13.5.1.3 South Korea Market Analysis, ByClinical Types
13.5.1.4 South Korea Market Analysis, By End-Users
13.6. AUSTRALIA
13.6.1.1 Australia Market Analysis, By Product Type
13.6.1.2 Australia Market Analysis, By Intake Mode
13.6.1.3 Australia Market Analysis, By Clinical Types
13.6.1.4 Australia Market Analysis, By End-Users
14. MIDDLE EAST AND AFRICA (MEA) GAUCHER DISEASE MARKET
14.1. OVERVIEW
14.1.1.1 MEA Market Analysis, By Product Type
14.1.1.2 MEA Market Analysis, By Intake Mode
14.1.1.3 MEA Market Analysis, By Clinical Types
14.1.1.4 MEA Market Analysis, By End-Users
14.2. SOUTH AFRICA
14.2.1.1 South Africa Market Analysis, By Product Type
14.2.1.2 South Africa Market Analysis, By Intake Mode
14.2.1.3 South Africa Market Analysis, By Clinical Types
14.2.1.4 South Africa Market Analysis, By End-Users
14.3. SAUDI ARABIA
14.3.1.1 Saudi Arabia Market Analysis, By Product Type
14.3.1.2 Saudi Arabia Market Analysis, By Intake Mode
14.3.1.3 Saudi Arabia Market Analysis, By Clinical Types
14.3.1.4 Saudi Arabia Market Analysis, By End-Users
14.4. ISRAEL
14.4.1.1 Israel Market Analysis, By Product Type
14.4.1.2 Israel Market Analysis, By Intake Mode
14.4.1.3 Israel Market Analysis, By Clinical Types
14.4.1.4 Israel Market Analysis, By End-Users
14.5. UAE
14.5.1.1 UAE Market Analysis, By Product Type
14.5.1.2 UAE Market Analysis, By Intake Mode
14.5.1.3 UAE Market Analysis, By Clinical Types
14.5.1.4 UAE Market Analysis, By End-Users
15. COMPANY PROFILES
15.1. PROTALIX BIOTHERAPEUTICS INC
15.1.1 COMPANY OVERVIEW
15.1.2 FINANCIAL PERFORMANCE
15.1.3 PRODUCT PORTFOLIO
15.2. PFIZER INC
15.2.1 COMPANY OVERVIEW
15.2.2 FINANCIAL PERFORMANCE
15.2.3 PRODUCT PORTFOLIO
15.3. ACTELION PHARMACEUTICALS LTD
15.3.1 COMPANY OVERVIEW
15.3.2 PRODUCT PORTFOLIO
15.3.3 RECENT DEVELOPMENT
15.4. SANOFI SA
15.4.1 COMPANY OVERVIEW
15.4.2 FINANCIAL PERFORMANCE
15.4.3 PRODUCT PORTFOLIO
15.5. TAKEDA PHARMACEUTICAL CO LTD
15.5.1 COMPANY OVERVIEW
15.5.2 FINANCIAL PERFORMANCE
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
By Clinical Type
The global Gaucher disease market has been segmented on the basis of clinical type into type I, type II and type III. The type I segment with around 80% share in the year 2018, occupies the largest market of Gaucher disease across the globe. Additionally, the type I segment is anticipated to cross a value of around USD 1500 million by the end of 2026 and is anticipated to flourish at a CAGR of around 3% over the forecast period. Further, the type III segment is estimated to grow with the highest CAGR of around 4% over the forecast period.
The global Gaucher disease market is segmented by regions into |North America, Latin America, Europe, Asia Pacific and Middle East and Africa. Among these regions, the market of Asia Pacific Gaucher disease is driven primarily by nations such as China, India and Japan, where China held the dominant market share of around 41% in the year 2018. Presence of the world’s largest population in the nation, which also raises the possibility of being infected by the Gaucher’s disease and the raising concern amongst the population to get vaccinated from such disease are some of the factors that predicts a significant growth of Gaucher disease market in upcoming years. Additionally, Asia Pacific is expected to expand by observing a growth rate of around 1.30x during the assessment period, which in turn is estimated to have a positive effect on the demand for global Gaucher disease treatment in the long run.
Further, U.S. and Canada are the prominent countries that are driving the growth of the North America Gaucher disease market. Increasing expenditure of the government on healthcare sector signifies the growth of the North America Gaucher disease market.
The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Growth Indicators
There is an increasing concern for the rising incidences of Gaucher disease amongst people around the globe as the risk of developing the disease increases with consanguinity in the family. According to the statistics by the National Organization for Rare Disorders (NORD), around 6000 individuals have Gaucher disease in the United States alone. Although the disease is one of the most common genetic disorder amongst the Ashkenazic Jewish population, which forms about 75% of the world’s total Jewish population, yet the chances of gene mutation or transfer of disease to other individuals often raises the concern to treat these rare diseases in an important manner. Additionally, rising per capita expenditure on healthcare by several nations around the globe along with growing support and funding of the government of nations are some of the factors anticipated to drive the growth of the global Gaucher disease market.
Barriers
The high cost associated with the treatment of the disease and stringent norms of the government of several nations for the use of drugs and treatments of the disease are some of the factors anticipated to impact negatively towards the growth of the global Gaucher disease market.
Some of the affluent industry leaders in the global Gaucher disease market are Protalix Inc., Pfizer Inc., Actelion Pharmaceuticals Ltd., Sanofi and Takeda Pharmaceutical Company Limited.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: Increasing concern for the growing incidences of Gaucher disease amongst people around the globe is one of the major factors that is driving the growth of the market.
Ans: The market is anticipated to attain a CAGR of around 3% over the forecast period, i.e. 2019-2026.
Ans: The market in North America is anticipated to provide more business opportunities in the future.
Ans: The major players in the global Gaucher disease market are Protalix Inc., Pfizer Inc., Actelion Pharmaceuticals Ltd., Sanofi and Takeda Pharmaceutical Company Limited.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The type I segment, which is a sub-segment of the clinical type segment, held the largest market share of around 80% in the year 2018 is anticipated to show significant growth opportunity.
Ans: Concerns regarding high cost associated with the treatment of the disease and stringent norms of the government of several nations are some of the factors anticipated to act as a barrier towards the growth of the market.
Submit Your Request For Proposal (RFP)
